Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Sarcoma 2Head & Neck 2Gynecologic 2Gastrointestinal 2Breast 2

Conditions

Colorectal Neoplasms 4Melanoma 3Breast Neoplasms 3Urogenital Neoplasms 2Stomach Neoplasms 2Sarcoma 2Ovarian Neoplasms 2Lung Neoplasms 2Liver Neoplasms 2Head and Neck Neoplasms 2Neoplasm Metastasis 1Inflammation 1Fatigue 1Cognitive Dysfunction 1Brain Neoplasms 1Behavior 1

Interventions

Oxaliplatin 295Capecitabine 209Fluorouracil 183Cisplatin 172Docetaxel 140S 1 (combination) 135Paclitaxel 128Leucovorin 117Irinotecan 110pembrolizumab 104Trastuzumab 75Nivolumab 59apatinib 57Drug Therapy 52sintilimab 46Surgical Procedures, Operative 45Ramucirumab 40Radiotherapy 40Bevacizumab 37Hyperthermic Intraperitoneal Chemotherapy 34Epirubicin 32titanium silicide 31tislelizumab 31Carboplatin 31Gastrectomy 28Cyclophosphamide 27XELOX 25Tegafur 24Folfox protocol 23Albumin-Bound Paclitaxel 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Stomach Neoplasms × Riluzole × Clear all
NCT07447050 2026-03-03

Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial

University of California, Irvine

Phase 2 Recruiting
24 enrolled
BreastGastrointestinalGynecologicHead & NeckSarcomaThoracic

Breast Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Sarcoma, Stomach Neoplasms, Urogenital Neoplasms, Colorectal Neoplasms

NCT06580002 2025-06-26

Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial

University of California, Irvine

Phase 2 Recruiting
51 enrolled
BreastGastrointestinalGynecologicHead & NeckSarcomaThoracic

Breast Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Sarcoma, Stomach Neoplasms, Urogenital Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡